| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 101 | 2023 | 374 | 21.020 |
Why?
|
| Infant | 61 | 2023 | 3046 | 2.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2022 | 2438 | 2.010 |
Why?
|
| N-Myc Proto-Oncogene Protein | 20 | 2023 | 36 | 1.960 |
Why?
|
| Child, Preschool | 52 | 2023 | 3612 | 1.870 |
Why?
|
| Anti-HIV Agents | 4 | 2021 | 149 | 1.820 |
Why?
|
| Opsoclonus-Myoclonus Syndrome | 3 | 2020 | 4 | 1.790 |
Why?
|
| HIV Infections | 10 | 2022 | 772 | 1.590 |
Why?
|
| Child | 58 | 2023 | 6927 | 1.540 |
Why?
|
| 3-Iodobenzylguanidine | 8 | 2022 | 19 | 1.450 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 1313 | 1.330 |
Why?
|
| Gene Amplification | 10 | 2021 | 131 | 1.310 |
Why?
|
| Induction Chemotherapy | 5 | 2022 | 147 | 1.290 |
Why?
|
| Prognosis | 34 | 2023 | 3679 | 1.270 |
Why?
|
| Disease-Free Survival | 24 | 2023 | 1204 | 1.230 |
Why?
|
| Oncogene Proteins | 13 | 2015 | 59 | 1.160 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1464 | 1.110 |
Why?
|
| Humans | 117 | 2023 | 86643 | 1.060 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 252 | 1.020 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2023 | 81 | 0.940 |
Why?
|
| Pelvic Neoplasms | 3 | 2014 | 45 | 0.930 |
Why?
|
| Antineoplastic Agents | 13 | 2016 | 2360 | 0.920 |
Why?
|
| 5-Methylcytosine | 3 | 2022 | 112 | 0.900 |
Why?
|
| Antibodies, Monoclonal | 8 | 2021 | 1376 | 0.890 |
Why?
|
| Neoplasm Staging | 23 | 2023 | 1939 | 0.880 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2023 | 71 | 0.880 |
Why?
|
| Immunotherapy | 8 | 2021 | 629 | 0.860 |
Why?
|
| Nuclear Proteins | 13 | 2015 | 696 | 0.850 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2022 | 1197 | 0.840 |
Why?
|
| HIV-1 | 3 | 2021 | 163 | 0.820 |
Why?
|
| Cell Proliferation | 5 | 2019 | 1578 | 0.800 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 56 | 0.790 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2020 | 66 | 0.780 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2020 | 11 | 0.750 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 92 | 0.730 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2022 | 878 | 0.720 |
Why?
|
| DNA Methylation | 4 | 2022 | 628 | 0.720 |
Why?
|
| Adolescent | 34 | 2021 | 8981 | 0.710 |
Why?
|
| Female | 59 | 2022 | 44532 | 0.710 |
Why?
|
| Stem Cell Transplantation | 8 | 2019 | 183 | 0.690 |
Why?
|
| Epigenomics | 1 | 2019 | 100 | 0.680 |
Why?
|
| Chromosome Aberrations | 6 | 2020 | 387 | 0.670 |
Why?
|
| Naphthyridines | 1 | 2019 | 53 | 0.660 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 160 | 0.630 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2016 | 689 | 0.610 |
Why?
|
| Male | 48 | 2021 | 40965 | 0.600 |
Why?
|
| Cell Line, Tumor | 12 | 2022 | 2426 | 0.600 |
Why?
|
| Prednisone | 1 | 2017 | 258 | 0.590 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 318 | 0.590 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.590 |
Why?
|
| Palmitic Acid | 1 | 2016 | 26 | 0.580 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.580 |
Why?
|
| Risk Factors | 19 | 2021 | 5417 | 0.580 |
Why?
|
| Survival Rate | 14 | 2021 | 1863 | 0.570 |
Why?
|
| Combined Modality Therapy | 9 | 2023 | 1686 | 0.570 |
Why?
|
| Infant, Newborn | 14 | 2021 | 2379 | 0.560 |
Why?
|
| Medical Oncology | 3 | 2021 | 359 | 0.560 |
Why?
|
| Isotretinoin | 3 | 2021 | 23 | 0.550 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 196 | 0.530 |
Why?
|
| Altruism | 1 | 2015 | 35 | 0.530 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 339 | 0.510 |
Why?
|
| Interleukin-2 | 4 | 2022 | 249 | 0.500 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 2271 | 0.500 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 3640 | 0.500 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2017 | 80 | 0.480 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 266 | 0.470 |
Why?
|
| Genomics | 3 | 2021 | 720 | 0.460 |
Why?
|
| Radiation Injuries | 1 | 2014 | 155 | 0.460 |
Why?
|
| Cohort Studies | 13 | 2021 | 2767 | 0.440 |
Why?
|
| Risk Assessment | 11 | 2023 | 2261 | 0.440 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2020 | 17 | 0.440 |
Why?
|
| Salvage Therapy | 4 | 2021 | 233 | 0.440 |
Why?
|
| Hypoxia | 2 | 2022 | 641 | 0.440 |
Why?
|
| Radiotherapy | 1 | 2014 | 328 | 0.430 |
Why?
|
| Pediatrics | 2 | 2021 | 344 | 0.430 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2020 | 68 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2021 | 592 | 0.410 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 176 | 0.410 |
Why?
|
| Treatment Outcome | 14 | 2022 | 7993 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2357 | 0.410 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 66 | 0.400 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 11 | 0.400 |
Why?
|
| Young Adult | 16 | 2021 | 5976 | 0.400 |
Why?
|
| Algorithms | 1 | 2019 | 1830 | 0.390 |
Why?
|
| Age Factors | 11 | 2021 | 1851 | 0.390 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 192 | 0.390 |
Why?
|
| Prospective Studies | 11 | 2023 | 4213 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 860 | 0.390 |
Why?
|
| Quinoxalines | 1 | 2011 | 50 | 0.380 |
Why?
|
| Pyridines | 2 | 2012 | 310 | 0.380 |
Why?
|
| Iodine Radioisotopes | 4 | 2022 | 134 | 0.380 |
Why?
|
| Neoplasm Metastasis | 7 | 2019 | 1056 | 0.370 |
Why?
|
| Parents | 3 | 2023 | 272 | 0.360 |
Why?
|
| Palliative Care | 2 | 2023 | 257 | 0.360 |
Why?
|
| Recurrence | 5 | 2023 | 1139 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 311 | 0.340 |
Why?
|
| International Cooperation | 3 | 2020 | 127 | 0.340 |
Why?
|
| Biomedical Research | 3 | 2021 | 376 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 589 | 0.330 |
Why?
|
| Health Status Disparities | 1 | 2010 | 170 | 0.330 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 916 | 0.310 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 859 | 0.300 |
Why?
|
| Survivors | 3 | 2022 | 226 | 0.300 |
Why?
|
| Adult | 22 | 2021 | 25648 | 0.290 |
Why?
|
| Ganglioneuroblastoma | 2 | 2018 | 4 | 0.280 |
Why?
|
| Risk | 4 | 2019 | 674 | 0.270 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1384 | 0.270 |
Why?
|
| United States | 6 | 2021 | 6672 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2022 | 645 | 0.260 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2022 | 112 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 11 | 3 | 2020 | 106 | 0.250 |
Why?
|
| Mixed Function Oxygenases | 2 | 2022 | 68 | 0.240 |
Why?
|
| Genome-Wide Association Study | 3 | 2017 | 1621 | 0.240 |
Why?
|
| Survival Analysis | 7 | 2021 | 1538 | 0.240 |
Why?
|
| Gangliosides | 2 | 2016 | 10 | 0.240 |
Why?
|
| Thoracic Neoplasms | 2 | 2014 | 64 | 0.240 |
Why?
|
| Radionuclide Imaging | 3 | 2021 | 220 | 0.240 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 331 | 0.240 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2016 | 153 | 0.240 |
Why?
|
| Gene Frequency | 2 | 2017 | 677 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2009 | 105 | 0.230 |
Why?
|
| Disease Progression | 5 | 2014 | 1531 | 0.230 |
Why?
|
| Lymph Nodes | 2 | 2019 | 533 | 0.220 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 25 | 0.220 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2013 | 67 | 0.220 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 322 | 0.220 |
Why?
|
| Watchful Waiting | 2 | 2013 | 60 | 0.220 |
Why?
|
| Ferritins | 2 | 2020 | 29 | 0.220 |
Why?
|
| Time Factors | 6 | 2019 | 5210 | 0.220 |
Why?
|
| Cell Hypoxia | 3 | 2022 | 164 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2020 | 100 | 0.220 |
Why?
|
| Brain Neoplasms | 3 | 2014 | 763 | 0.220 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.210 |
Why?
|
| Central Nervous System | 1 | 2023 | 151 | 0.210 |
Why?
|
| Transcriptome | 2 | 2016 | 580 | 0.210 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 162 | 0.200 |
Why?
|
| Cancer Survivors | 1 | 2022 | 85 | 0.200 |
Why?
|
| Neoplasms | 3 | 2021 | 2898 | 0.200 |
Why?
|
| Nomograms | 1 | 2020 | 28 | 0.190 |
Why?
|
| Retrospective Studies | 8 | 2023 | 8489 | 0.190 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.190 |
Why?
|
| Genotype | 2 | 2017 | 1851 | 0.190 |
Why?
|
| Research Report | 3 | 2021 | 44 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 185 | 0.180 |
Why?
|
| Rituximab | 1 | 2020 | 116 | 0.180 |
Why?
|
| Incidence | 4 | 2022 | 1577 | 0.180 |
Why?
|
| Cell Differentiation | 4 | 2015 | 1458 | 0.180 |
Why?
|
| Mice | 5 | 2019 | 11352 | 0.180 |
Why?
|
| Attitude to Death | 1 | 2019 | 36 | 0.180 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 34 | 0.180 |
Why?
|
| Mitotic Index | 2 | 2020 | 20 | 0.170 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 30 | 0.170 |
Why?
|
| Cell Movement | 3 | 2022 | 758 | 0.170 |
Why?
|
| Drug Interactions | 1 | 2019 | 248 | 0.170 |
Why?
|
| Cell Cycle | 2 | 2011 | 502 | 0.170 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 1169 | 0.170 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2009 | 64 | 0.170 |
Why?
|
| Ganglioneuroma | 1 | 2018 | 9 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2017 | 172 | 0.170 |
Why?
|
| Social Stigma | 1 | 2019 | 52 | 0.170 |
Why?
|
| Heterografts | 1 | 2019 | 98 | 0.170 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 263 | 0.170 |
Why?
|
| Mitosis | 2 | 2020 | 153 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2017 | 814 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 138 | 0.160 |
Why?
|
| Lymphoma | 1 | 2019 | 262 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 418 | 0.160 |
Why?
|
| Receptors, KIR | 1 | 2017 | 10 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 250 | 0.160 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2017 | 7 | 0.160 |
Why?
|
| Ataxia | 1 | 2017 | 37 | 0.150 |
Why?
|
| Neurologic Examination | 1 | 2017 | 118 | 0.150 |
Why?
|
| Pheochromocytoma | 1 | 2017 | 49 | 0.150 |
Why?
|
| Nurse's Role | 1 | 2017 | 12 | 0.150 |
Why?
|
| Biomarkers | 3 | 2020 | 1718 | 0.150 |
Why?
|
| Age of Onset | 2 | 2015 | 310 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 257 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.150 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.140 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 63 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 532 | 0.140 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 76 | 0.140 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.140 |
Why?
|
| Mutation | 3 | 2016 | 3968 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2017 | 272 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2017 | 127 | 0.140 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.140 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 78 | 0.140 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.140 |
Why?
|
| Melphalan | 1 | 2016 | 98 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2014 | 999 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2017 | 129 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 1673 | 0.140 |
Why?
|
| Thiamine | 1 | 2015 | 8 | 0.130 |
Why?
|
| Wernicke Encephalopathy | 1 | 2015 | 6 | 0.130 |
Why?
|
| Melanoma | 1 | 2019 | 459 | 0.130 |
Why?
|
| Genes, myc | 1 | 2015 | 39 | 0.130 |
Why?
|
| Autografts | 4 | 2017 | 28 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 71 | 0.130 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 486 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 329 | 0.130 |
Why?
|
| Apoptosis | 2 | 2019 | 1683 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 49 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 348 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 977 | 0.130 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 294 | 0.130 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2014 | 19 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 94 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 236 | 0.120 |
Why?
|
| Genetic Therapy | 1 | 2016 | 342 | 0.120 |
Why?
|
| Karyotyping | 1 | 2014 | 250 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2012 | 171 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 174 | 0.120 |
Why?
|
| Cell Survival | 1 | 2016 | 969 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 930 | 0.120 |
Why?
|
| Dacarbazine | 2 | 2013 | 102 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2015 | 160 | 0.120 |
Why?
|
| Orbital Neoplasms | 1 | 2013 | 17 | 0.120 |
Why?
|
| Animals | 5 | 2019 | 26582 | 0.120 |
Why?
|
| Patient Selection | 2 | 2015 | 685 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 24 | 0.120 |
Why?
|
| SEER Program | 1 | 2014 | 190 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 39 | 0.120 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2705 | 0.120 |
Why?
|
| Immunomagnetic Separation | 1 | 2013 | 8 | 0.120 |
Why?
|
| Camptothecin | 2 | 2013 | 189 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2012 | 678 | 0.120 |
Why?
|
| Cell Nucleolus | 1 | 2013 | 23 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2012 | 153 | 0.120 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2013 | 43 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 663 | 0.120 |
Why?
|
| Pyrimidines | 2 | 2018 | 370 | 0.120 |
Why?
|
| Computational Biology | 1 | 2016 | 528 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2012 | 790 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 114 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1805 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 458 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 120 | 0.110 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2012 | 55 | 0.110 |
Why?
|
| Fenretinide | 1 | 2011 | 2 | 0.100 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2011 | 33 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1801 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 128 | 0.100 |
Why?
|
| Topotecan | 1 | 2011 | 45 | 0.100 |
Why?
|
| Drug Monitoring | 3 | 2018 | 118 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2013 | 300 | 0.100 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2011 | 27 | 0.100 |
Why?
|
| Niacinamide | 1 | 2011 | 116 | 0.100 |
Why?
|
| Loss of Heterozygosity | 3 | 2018 | 85 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 114 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 865 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2011 | 391 | 0.100 |
Why?
|
| Radiopharmaceuticals | 3 | 2018 | 180 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 552 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2008 | 66 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 373 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 763 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2013 | 355 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2012 | 261 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 293 | 0.090 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 72 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 299 | 0.090 |
Why?
|
| Pregnancy Rate | 1 | 2009 | 20 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1749 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 353 | 0.090 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1753 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 1208 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2007 | 72 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2008 | 183 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2008 | 123 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 1052 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 196 | 0.070 |
Why?
|
| Consensus | 2 | 2018 | 335 | 0.070 |
Why?
|
| Communication | 2 | 2020 | 441 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 357 | 0.070 |
Why?
|
| Etoposide | 2 | 2018 | 196 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2018 | 295 | 0.060 |
Why?
|
| Carboplatin | 2 | 2018 | 286 | 0.060 |
Why?
|
| Viral Load | 2 | 2019 | 148 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2501 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 1075 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1019 | 0.060 |
Why?
|
| Goals | 1 | 2023 | 67 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2014 | 285 | 0.060 |
Why?
|
| Capsules | 2 | 2013 | 38 | 0.060 |
Why?
|
| Morbidity | 1 | 2022 | 148 | 0.050 |
Why?
|
| Vincristine | 1 | 2021 | 111 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2014 | 547 | 0.050 |
Why?
|
| Diploidy | 1 | 2020 | 30 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2014 | 712 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 2262 | 0.050 |
Why?
|
| Therapies, Investigational | 1 | 2019 | 17 | 0.050 |
Why?
|
| Alabama | 1 | 2019 | 13 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2003 | 510 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2019 | 22 | 0.040 |
Why?
|
| Decision Making | 2 | 2019 | 642 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2013 | 839 | 0.040 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 479 | 0.040 |
Why?
|
| Hepatomegaly | 1 | 2018 | 15 | 0.040 |
Why?
|
| Filgrastim | 1 | 2018 | 56 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1014 | 0.040 |
Why?
|
| Azepines | 1 | 2018 | 20 | 0.040 |
Why?
|
| Quality of Life | 2 | 2019 | 1585 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 594 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 107 | 0.040 |
Why?
|
| Ecosystem | 1 | 2021 | 316 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2011 | 782 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2017 | 4 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 927 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 39 | 0.040 |
Why?
|
| Thymus Hyperplasia | 1 | 2016 | 3 | 0.040 |
Why?
|
| Pregnancy | 3 | 2009 | 2894 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 287 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 7 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 145 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 138 | 0.040 |
Why?
|
| Ligands | 1 | 2017 | 433 | 0.040 |
Why?
|
| Glutathione | 1 | 2016 | 104 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 341 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 303 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 150 | 0.030 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2601 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2018 | 574 | 0.030 |
Why?
|
| Acetylation | 1 | 2015 | 121 | 0.030 |
Why?
|
| RNA, Viral | 2 | 2008 | 327 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1379 | 0.030 |
Why?
|
| DNA Repair | 1 | 2016 | 356 | 0.030 |
Why?
|
| Cyclohexylamines | 1 | 2014 | 7 | 0.030 |
Why?
|
| Suspensions | 1 | 2013 | 6 | 0.030 |
Why?
|
| Middle Aged | 3 | 2019 | 25028 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 63 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 610 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 292 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 34 | 0.030 |
Why?
|
| Quality Control | 1 | 2014 | 117 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 364 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 79 | 0.030 |
Why?
|
| Cytosine | 1 | 2014 | 127 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3362 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 303 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 151 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 273 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 311 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 151 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 2012 | 43 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2012 | 110 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 146 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 329 | 0.030 |
Why?
|
| Ploidies | 1 | 2011 | 40 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 554 | 0.030 |
Why?
|
| Tretinoin | 1 | 2012 | 126 | 0.030 |
Why?
|
| Thymopentin | 1 | 2011 | 2 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 2011 | 20 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1961 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 265 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2012 | 271 | 0.030 |
Why?
|
| Research | 1 | 2012 | 253 | 0.030 |
Why?
|
| Antibodies | 1 | 2013 | 350 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1981 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2010 | 66 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 172 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 99 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1186 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 94 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 468 | 0.020 |
Why?
|
| North America | 1 | 2010 | 180 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 204 | 0.020 |
Why?
|
| Japan | 1 | 2010 | 307 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 18415 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 309 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 736 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 684 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 504 | 0.020 |
Why?
|
| Gravidity | 1 | 2009 | 7 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 896 | 0.020 |
Why?
|
| Sex Education | 1 | 2009 | 9 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2009 | 44 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 63 | 0.020 |
Why?
|
| Contraceptive Agents, Female | 1 | 2009 | 31 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6509 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 27 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 894 | 0.020 |
Why?
|
| Birth Weight | 1 | 2008 | 145 | 0.020 |
Why?
|
| Body Height | 1 | 2008 | 99 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 1540 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2007 | 58 | 0.020 |
Why?
|
| Phenotype | 1 | 2014 | 2378 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2007 | 90 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 926 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1351 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 469 | 0.020 |
Why?
|
| Triglycerides | 1 | 2007 | 232 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2007 | 165 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 247 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 508 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2232 | 0.020 |
Why?
|
| Hepatitis A Vaccines | 1 | 2003 | 3 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 1 | 2003 | 3 | 0.020 |
Why?
|
| Mumps virus | 1 | 2003 | 3 | 0.020 |
Why?
|
| Tetanus Toxoid | 1 | 2003 | 10 | 0.020 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2003 | 5 | 0.020 |
Why?
|
| Azithromycin | 1 | 2003 | 13 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2003 | 95 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2003 | 78 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2012 | 3241 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 746 | 0.010 |
Why?
|